Judge: Investors Failed To Identify False Statements About Clinical Trial

NEW YORK — A federal judge in New York dismissed investors’ putative class action against a clinical biopharmaceutical company and certain of its senior officers and board members for making allegedly...

Already a subscriber? Click here to view full article